The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing said substituted-7-azabicyclo-[2.2.1]heptyl derivatives. The present invention also relates to certain intermediates for producing such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as a synthetic method for producing such intermediates. The present invention also relates to pharmaceutical compositions comprising such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as their use as medicaments for the treatment of diseases mediated by a Nicotinic Acetylcholine Receptor or a receptor being a member of the Neurotransmitter-gated Ion Channel Superfamily, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and nicotine addiction.
本发明涉及一组具有
生物活性的取代-7-
氮杂双环[2.2.1]庚基衍
生物。本发明还涉及用于制备所述取代-7-
氮杂双环[2.2.1]庚基衍
生物的合成方法。本发明还涉及用于制备此类取代-7-
氮杂双环[2.2.1]庚基衍
生物的某些中间体,以及用于制备此类中间体的合成方法。本发明还涉及包含此类取代-7-
氮杂双环[2.2.1]庚基衍
生物的药物组合物,以及它们作为治疗由
尼古丁乙酰胆碱受体或神经递质门控离子通道超家族成员介导的疾病的药物的用途,如疼痛、阿尔茨海默病、帕
金森病、精神分裂症、癫痫和
尼古丁成瘾。